Condition: Peripheral T-cell Lymphoma · Sponsor: Yanyan Liu
The phase Ib part of this study aims to determine the recommended phase II dose （RP2D）of linperlisib in combination with chidamide for the treatment of peripheral T-cell lymphoma (PTCL). The phase IIa part is designed to evaluate the preliminary efficacy and safety of the linperlisib plus chidamide regimen in newly diagnosed PTCL patients. The phase IIb part compares the efficacy and safety of linperlisib combined with chidamide versus the standard CHOP (CHOP-like) regimen in newly diagnosed PTCL patients.
This description comes directly from the study's public registry record.
Yanyan Liu · 86 037165587791 · yyliu@zzu.edu.cn
Zheng Yan · 86 13598097015 · zlyyyanzheng3920@zzu.edu.cn
Always discuss trial participation with your own doctor first.
| Affiliated Cancer Hospital of Zhengzhou University | Zhengzhou, Henan, China | Recruiting |
| Liling Zhang | Wuhan, Hubei, China | Recruiting |
| Yajun Li | Changsha, Hunan, China | Recruiting |
| Ming Jiang | Chengdu, Sichuan, China | Recruiting |
| Huilai Zhang | Tianjin, Tianjin Municipality, China | Recruiting |
| Cong Li | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06421948